
    
      This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the
      efficacy and safety of vadadustat versus darbepoetin alfa for the correction or maintenance
      treatment in subjects with anemia secondary to CKD who have recently initiated dialysis
      treatment for end-stage renal disease.
    
  